Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Director departure
|
Good Works II Acquisition Corp.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/22/2023 |
8-K
| Other Events Interactive Data |
01/20/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
12/29/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
10/13/2022 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submiss...
Docs:
|
"DIRECT BIOLOGICS, INC., DB MERGER SUB, INC., DB DRE LLC, and DIRECT BIOLOGICS, LLC",
"Amendment to Amended and Restated Certificate of Incorporation of Good Works II Acquisition Corp.",
"Amended and Restated Business Combination Marketing Agreement",
"Good Works II Acquisition Corp. and Direct Biologics, LLC Announce a Definitive Agreement for a Business Combination HOUSTON and AUSTIN, Texas – Good Works II Acquisition Corp. , a publicly traded special purpose acquisition company , and Direct Biologics, LLC , a late-stage biotechnology company, today announced the signing of a definitive agreement that, upon the satisfaction of all closing conditions, will result in Direct Biologics becoming a publicly traded company. Upon transaction close, which is expected to occur in the first half of 2023, the combined company will be named Direct Biologics, Inc. and shares of its common stock are expected to trade on the Nasdaq Capital Market. Cary Grossman, Chief Executive Officer of Good Works II, commented, “We formed Good Works II with the obj...",
"INVESTOR PRESENTATION" |
|
09/27/2022 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
05/24/2022 |
8-K
| Quarterly results |
05/23/2022 |
8-K
| Quarterly results |
08/19/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
07/20/2021 |
8-K
| Quarterly results |
07/14/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs:
|
"FORM 8-K",
"Underwriting Agreement, by and between the Company and I-Bankers Securities, Inc., as representative of the several underwriters",
"Business Combination Marketing Agreement, by and between the Company and the Representative",
"Amended and Restated Certificate of Incorporation",
"Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent",
"Letter Agreement, dated July 9, by and among the Company, I-B Good Works 2, LLC and each of the officers and directors of the Company",
"Investment Management Trust Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as trustee",
"Registration Rights Agreement, by and among the Company and certain holders party thereto",
"Administrative Services Agreement, by and between the Company and Shoreline Capital Advisors, Inc",
"Good Works II Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering",
"Good Works II Acquisition Corp. Announces Closing of $230,000,000 Initial Public Offering, Including Full Exercise of Underwriter Over-Allotment Option" |
|
|
|